The Effects of Bromelain Supplement in Patients With Ulcerative Colitis

Last updated: April 6, 2024
Sponsor: National Nutrition and Food Technology Institute
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colic

Liver Disorders

Ulcerative Colitis

Treatment

Placebo

Bromlein

Clinical Study ID

NCT06351696
43008563
  • Ages 18-70
  • All Genders

Study Summary

In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks.

IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • active mild to moderate UC
  • no other chronic disorders

Exclusion

Exclusion Criteria:

  • changed the type and dosage of their medication in the last month
  • those who have relapses that required hospitalization and change the type and dosageof medications during the intervention
  • patients who do not want to continue the study protocol

Study Design

Total Participants: 84
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
April 20, 2024
Estimated Completion Date:
August 10, 2024

Connect with a study center

  • Azita Hekmatdoost

    Tehran, Middle East 19835
    Iran, Islamic Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.